Physician profile
Daniel H Jo
NPI 1508150590
$11,905.88
in general payments reported to CMS, 2019-2025
28 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $87.02 · 2021: $849 · 2022: $1,545 · 2023: $3,085 · 2024: $3,909 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,225 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,225.02 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,163.41 | 2020-2025 | Tavneos, Krystexxa, Evenity |
| Ucb, INC. | $1,647.62 | 2021-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,623.93 | 2021-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,017.35 | 2021-2025 | |
| Glaxosmithkline, LLC. | $804.90 | 2020-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $608.69 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $507.28 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $437.88 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $424.87 | 2023-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $420.29 | 2021-2022 | |
| Horizon Therapeutics Plc | $364.97 | 2021-2023 | Krystexxa |
| Radius Health, INC. | $364.73 | 2021-2025 | Tymlos |
| Pfizer INC. | $310.04 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $210.27 | 2024 | Arcalyst |
| Aurinia Pharma U.S., INC. | $187.27 | 2023-2024 | Lupkynis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $135.91 | 2025 | M22 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.92 | 2021-2025 | Ofev, Cyltezo |
| Collegium Pharmaceutical, INC. | $100.71 | 2021-2023 | Xtampza, Belbuca |
| Alexion Pharmaceuticals, INC. | $97.24 | 2023-2025 | Strensiq |
| Exact Sciences Corporation | $94.84 | 2023 | Cologuard Collection Kit |
| Kiniksa Pharmaceuticals, LTD. | $53.52 | 2023 | Arcalyst |
| Genzyme Corporation | $49.57 | 2023 | |
| Merz North America, INC. | $47.36 | 2025 | |
| Lilly USA, LLC | $46.25 | 2025 | Taltz |
| Celltrion USA INC. | $23.78 | 2025 | Vegzelma |
| Revance Therapeutics, INC. | $22.32 | 2025 | |
| Fidia Pharma USA INC. | $21.67 | 2025 | Hymovis |
| E.R. Squibb & Sons, L.L.C. | $16.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.